HELIOSPECTRA AB Redeye provides an update following Heliospectra’s Q1’23 report, where an increased gross margin, a well-controlled cost basis, and management’s anticipation of robust order intake in Q2’23 support an optimistic outlook. Sales and order intake came in slightly lower than expected. Hence, we have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
